Nadežda Basara

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler et autres

de, at (code pays fourni par la source)

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Stephanie Sasse, Paul J. Bröckelmann, Jesko Momotow, Annette Plütschow et autres

In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule …

de, us (code pays fourni par la source)

Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Dietrich W. Beelen, Matthias Stelljes, Péter Reményi, Eva‐Maria Wagner‐Drouet et autres

Abstract The phase III study was designed to compare event‐free survival (EFS) after treosulfan‐based conditioning with a widely applied reduced‐intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell …

de, hu, it, fr, pl (code pays fourni par la source)

Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial

Friedrich Stölzel, Matthias Stelljes, Dietrich W. Beelen, Mirosław Markiewicz et autres

Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS)

Matthias Stelljes, Rudolf Trenschel, Dietrich W. Beelen, Mirosław Markiewicz et autres

Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)

William Krüger, Carsten Hirt, Nadežda Basara, Herbert G. Sayer et autres

Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma with an often aggressive course, incurable by chemotherapy. Consolidation with high-dose therapy and autologous stem cell transplantation (autoSCT) has a low transplant-related mortality but does not lead to a survival plateau. Allogeneic stem cell …

de (code pays fourni par la source)

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Stephanie Sasse, Jesko Momotow, Annette Plütschow, Andreas Hüttmann et autres

INTRODUCTION: The outcome of patients (pts) with classical Hodgkin Lymphoma (cHL) experiencing relapse after high dose chemotherapy, brentuximab vedotin (BV) and anti-PD1 antibody (Ab) treatment is poor and in most patients the duration of the response to this treatment is rather short. …

de (code pays fourni par la source)

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Verena I. Gaidzik, Verena Mayr-Benedikter, Daniela Weber, Anika Schrade et autres

Background: CPX-351, a liposomal formulation of daunorubicin and cytarabine in the fixed molar ratio (1:5), is approved for the treatment of adult patients (pts) with newly diagnosed acute myeloid leukemia (AML) with myelodysplasia-related changes and therapy-related AML (t-AML). To explore the potential …

de, us (code pays fourni par la source)

High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early Colon cancer (CC); real world data from the AIO molecular registry Colopredict Plus

Stefanie Noepel-Duennebacke, Hendrik Juette, Anke Reinacher‐Schick, Andrea Tannapfel et autres

Colorectal cancer is one of the leading malignancies and still accounts for almost 25 000 deaths in Germany each year. Although there is accumulating data on the molecular basis, treatment and clinical outcome of patients within clinical trials evidence from the real-world …

de (code pays fourni par la source)

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

Richard F. Schlenk, Peter Paschka, Julia Krzykalla, Daniela Weber et autres

PURPOSE High CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial to evaluate GO in combination with intensive induction and consolidation therapy …

de, at (code pays fourni par la source)

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes, Christoph Groth et autres

de, hu, it, fr, se, pl (code pays fourni par la source)

Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitor Therapy: Insights from VARGADO, A Prospective Study in Patients with Lung Adenocarcinoma

Christian Grohé, Wolfgang Gleiber, Siegfried Haas, Christoph Losem et autres

Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARGADO is a prospective, noninterventional study. We describe initial data …

de, ee (code pays fourni par la source)